About Werewolf Therapeutics, Inc. - Common Stock (HOWL)
Werewolf Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. The company specializes in harnessing the power of its proprietary Werewolf platform, which is designed to create programmable therapeutics that can target and modulate the immune system's response to enhance treatment efficacy. By integrating novel drug design and advanced biological engineering techniques, Werewolf aims to deliver more effective, tailored treatment options that improve patient outcomes in oncology and beyond. Read More
– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 –
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.Details for the poster presentations are as follows:
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 2:00 PM EDT on Monday, September 8, 2025, at the H.C. Wainwright 27th Annual Global Investment Conference, taking place on September 8-10, 2025.
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma –
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will speak at the upcoming KidneyCAN 7th Annual Kidney Cancer Research Summit taking place July 17-18 in Boston, Massachusetts.
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will participate in a panel discussion at the upcoming BIO International Convention taking place June 16-19 in Boston, Massachusetts.
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, at the Jefferies Global Healthcare Conference, taking place on June 3-5, 2025.
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak during the Hanson Wade Cytokine-Based Drug Development Summit taking place May 15-16 in Boston, Massachusetts.
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that management will participate in the following upcoming investor conferences in the month of May:
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting.
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will present a corporate overview at 1:30 PM ET on Monday, April 7, 2025, at the 24th Annual Needham Virtual Healthcare Conference, taking place on April 7–10, 2025.
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively –
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat from 11:20-11:50 AM on Tuesday, March 11, 2025, in Studio 3 at the Leerink Partners Global Biopharma Conference, taking place March 10-12, 2025, in Miami, Florida.
